A decision by the U.S. District Court for the District of New Jersey late Friday removed a key overhang on Amgen shares when it upheld two Enbrel patents at stake in a suit against Sandoz.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,